BR112018003264A2 - conjugados de aldeído e usos dos mesmos - Google Patents

conjugados de aldeído e usos dos mesmos

Info

Publication number
BR112018003264A2
BR112018003264A2 BR112018003264A BR112018003264A BR112018003264A2 BR 112018003264 A2 BR112018003264 A2 BR 112018003264A2 BR 112018003264 A BR112018003264 A BR 112018003264A BR 112018003264 A BR112018003264 A BR 112018003264A BR 112018003264 A2 BR112018003264 A2 BR 112018003264A2
Authority
BR
Brazil
Prior art keywords
aldehyde
hne
mda
pathogenesis
implicated
Prior art date
Application number
BR112018003264A
Other languages
English (en)
Inventor
Young Scott
brady Todd
A Kinney William
Original Assignee
Aldeyra Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aldeyra Therapeutics Inc filed Critical Aldeyra Therapeutics Inc
Publication of BR112018003264A2 publication Critical patent/BR112018003264A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/69—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/16—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with only hydrogen or carbon atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles

Abstract

a presente invenção fornece compostos e métodos de uso dos mesmos para o tratamento, prevenção e/ou redução de um risco de uma doença, transtorno ou condição na qual a toxicidade pelo aldeído está implicada na patogênese, incluindo transtornos oculares, transtornos cutâneos, condições associadas a efeitos prejudiciais de agentes que formam bolhas e doenças cardiovasculares e autoimunes, inflamatórias e neurológicas por meio de uso de uma amina primária para eliminar aldeídos tóxicos, tais como mda e hne.
BR112018003264A 2015-08-21 2016-08-22 conjugados de aldeído e usos dos mesmos BR112018003264A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562208278P 2015-08-21 2015-08-21
US201662315455P 2016-03-30 2016-03-30
US201662347464P 2016-06-08 2016-06-08
PCT/US2016/048064 WO2017035082A1 (en) 2015-08-21 2016-08-22 Aldehyde conjugates and uses thereof

Publications (1)

Publication Number Publication Date
BR112018003264A2 true BR112018003264A2 (pt) 2018-09-25

Family

ID=58100899

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018003264A BR112018003264A2 (pt) 2015-08-21 2016-08-22 conjugados de aldeído e usos dos mesmos

Country Status (14)

Country Link
US (3) US20180250306A1 (pt)
EP (1) EP3337470A4 (pt)
JP (2) JP6959650B2 (pt)
KR (1) KR20180073553A (pt)
CN (2) CN114085236A (pt)
AU (1) AU2016311163A1 (pt)
BR (1) BR112018003264A2 (pt)
CA (1) CA2996186A1 (pt)
CL (1) CL2018000462A1 (pt)
CO (1) CO2018002841A2 (pt)
HK (1) HK1256143A1 (pt)
IL (1) IL257615A (pt)
MX (1) MX2018002157A (pt)
WO (1) WO2017035082A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5042215B2 (ja) 2005-05-26 2012-10-03 ニューロン システムズ， インコーポレイテッド 網膜疾患を処置するための組成物および方法
KR102243169B1 (ko) 2013-01-23 2021-04-22 알데이라 테라퓨틱스, 아이엔씨. 독성 알데히드 관련된 질병 및 치료
EP3337486B1 (en) * 2015-08-21 2024-04-03 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
CA3016759A1 (en) 2016-02-28 2017-08-31 Aldeyra Therapeutics, Inc. Treatment of allergic eye conditions with cyclodextrins
AU2017264697A1 (en) 2016-05-09 2018-11-22 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
US20180050989A1 (en) * 2016-08-22 2018-02-22 Aldeyra Therapeutics, Inc. Aldehyde trapping compounds and uses thereof
WO2018170476A1 (en) 2017-03-16 2018-09-20 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
EP3694500A4 (en) * 2017-10-10 2021-06-30 Aldeyra Therapeutics, Inc. TREATMENT OF INFLAMMATORY DISORDERS
JP2021533154A (ja) 2018-08-06 2021-12-02 アルデイラ セラピューティクス， インコーポレイテッド 多形化合物およびその使用
CN115869258A (zh) 2018-09-25 2023-03-31 奥尔德拉医疗公司 用于治疗干眼病的调配物
WO2020118045A1 (en) * 2018-12-05 2020-06-11 Aldeyra Therapeutics, Inc. Injectable formulations
WO2020125659A1 (zh) * 2018-12-18 2020-06-25 南京明德新药研发有限公司 用于视网膜疾病的化合物
WO2020198064A1 (en) 2019-03-26 2020-10-01 Aldeyra Therapeutics, Inc. Ophthalmic formulations and uses thereof
BR112022012641A2 (pt) * 2019-12-27 2022-09-06 Lupin Ltd Compostos tricíclicos substituídos
EP4086241A4 (en) * 2019-12-30 2024-02-07 The Nat Institutes Of Pharmaceutical R&D Co Ltd TRICYCLIC COMPOUND AND PREPARATION METHOD AND MEDICAL USE THEREOF
US20230149383A1 (en) * 2020-04-13 2023-05-18 Aldeyra Therapeutics, Inc. Quinoline compounds for treating lung, liver, and kidney diseases, disorders, or conditions
US11753377B2 (en) 2020-06-17 2023-09-12 Zhuhai United Laboratories Co., Ltd. Crystal form of 2-methyl-2-propanol and amino-substituted aryl compound
CN115702144A (zh) * 2020-06-17 2023-02-14 南京明德新药研发有限公司 氨基吡啶类化合物
WO2022063325A1 (zh) * 2020-09-28 2022-03-31 南京明德新药研发有限公司 吡啶苯基类化合物的晶型及其制备方法
US20240092744A1 (en) * 2020-12-29 2024-03-21 The National Institutes of Pharmaceutical R&D Co., Ltd. Tricyclic compound, and preparation method therefor and medical use thereof
WO2022267930A1 (zh) * 2021-06-25 2022-12-29 中国医药研究开发中心有限公司 三环化合物及其制备方法和医药用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358948B1 (en) * 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
JP5042215B2 (ja) * 2005-05-26 2012-10-03 ニューロン システムズ， インコーポレイテッド 網膜疾患を処置するための組成物および方法
JP5793459B2 (ja) * 2012-03-30 2015-10-14 新日鐵住金ステンレス株式会社 加工性に優れた耐熱フェライト系ステンレス冷延鋼板、冷延素材用フェライト系ステンレス熱延鋼板及びそれらの製造方法
RU2015120478A (ru) * 2012-12-20 2017-01-25 Альдейра Терапьютикс, Инк. Пери-карбинолы
KR102243169B1 (ko) * 2013-01-23 2021-04-22 알데이라 테라퓨틱스, 아이엔씨. 독성 알데히드 관련된 질병 및 치료

Also Published As

Publication number Publication date
KR20180073553A (ko) 2018-07-02
US20180250306A1 (en) 2018-09-06
JP2018530524A (ja) 2018-10-18
JP7332186B2 (ja) 2023-08-23
CO2018002841A2 (es) 2018-07-10
JP2022000469A (ja) 2022-01-04
JP6959650B2 (ja) 2021-11-02
WO2017035082A1 (en) 2017-03-02
EP3337470A1 (en) 2018-06-27
CN114085236A (zh) 2022-02-25
US20220354857A1 (en) 2022-11-10
AU2016311163A1 (en) 2018-04-05
CL2018000462A1 (es) 2018-08-17
IL257615A (en) 2018-04-30
MX2018002157A (es) 2018-06-08
CN108135867A (zh) 2018-06-08
HK1256143A1 (zh) 2019-09-13
US20200246345A1 (en) 2020-08-06
CA2996186A1 (en) 2017-03-02
EP3337470A4 (en) 2019-02-27

Similar Documents

Publication Publication Date Title
BR112018003264A2 (pt) conjugados de aldeído e usos dos mesmos
BR112018003250A2 (pt) compostos deuterados e usos dos mesmos
CO2019001625A2 (es) Compuestos de captura de aldehído y usos de los mismos
MX2019012878A (es) Terapias para el tratamiento de enfermedades asociadas con la toxicidad del aldehido.
ECSP20030074A (es) Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
DOP2016000195A (es) Compuestos
DOP2016000295A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
CL2019000230A1 (es) Composiciones y métodos de inhibición del masp-3 para el tratamiento de diversas enfermedades y trastornos.
BR112018074185A2 (pt) 3-oxo-2,6-difenil-2,3-di-hidropiridazina-4-carboxamidas
BR112018000691A2 (pt) inibidores peptídicos do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias
MX2018000396A (es) Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4).
EA201890307A1 (ru) Индазольные и азаиндазольные соединения как ингибиторы irak-4
BR112017026739A2 (pt) compostos para uso no tratamento de distúrbios neuromusculares
DOP2018000204A (es) Moduladores alostéricos de receptores de acetilcolina nicotínicos
CL2017001046A1 (es) Inhibidoes del bromodominio
BR112018074454A2 (pt) composições e métodos de uso de nintedanib para tratar doenças oculares com neovascularização anormal
BR112018010564A2 (pt) composições farmacêuticas compreendendo levodopa amida e usos das mesmas
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
BR112018014675A2 (pt) novos derivados de cianoindolina substituída como inibidores de nik
EA201990400A1 (ru) Соединения и композиции и их применение
EA201792604A1 (ru) Ингибиторы аутотаксина и их применения
EA202090414A1 (ru) Соединения и их применение
UY37580A (es) Compuestos novedosos que inhiben la actividad de cinasa lrrk2
EA201691567A1 (ru) Способы лечения легких травм головного мозга
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements